文献速递皮肤肿瘤

多基因风险评分与临床风险评分预测黑色素瘤的比较

Genetics versus clinical risk scores for melanoma prediction.
PubMed 文献 · Br J Dermatol · 2026-01-01

本研究基于黑色素瘤全基因组关联研究荟萃分析(28 849 例患者、78 922 例对照)构建多基因风险评分(PRS),在加拿大老龄化纵向研究队列中调优,并在 QSkin 前瞻性队列(16 282 名 40–69 岁有遗传数据的参与者,随访 10 年新发侵袭性黑色素瘤 359 例)中独立验证。结果显示 PRS 优于任一单一临床危险因素,加入 MP16 临床模型后判别能力与净重分类均有改善。

要点

  • PRS 在 QSkin 队列中优于任何单一临床危险因素(c-index 0.643)。
  • PRS 加入 MP16 模型后 c-index 由 0.713 升至 0.729。
  • 将遗传风险信息纳入现有临床风险工具有助于改善黑色素瘤预测。

核心结论

  • 将遗传风险信息纳入现有临床风险工具可显著改善黑色素瘤的预测性能。
  • PRS 是 QSkin 队列中最强的黑色素瘤风险预测因子,其次为曾接受光化性角化病治疗和既往手术切除皮肤癌。

研究设计与样本

  • PRS 源自黑色素瘤全基因组关联研究荟萃分析,纳入 20 项研究、28 849 例黑色素瘤患者和 78 922 例对照。
  • PRS 在加拿大老龄化纵向研究队列中调优,该队列含 528 例黑色素瘤患者和 17 787 例对照。
  • 在 QSkin 前瞻性队列中独立验证,含 16 282 名基线 40–69 岁有遗传数据的参与者,10 年随访期间识别 359 例新发侵袭性黑色素瘤。
  • 将 PRS 与 14 项自报临床因素及 MP16 临床预测模型进行比较。

主要发现

  • PRS 在 QSkin 中优于任何其他单一临床危险因素(c-index 0.643)。
  • 基线风险模型(年龄、性别、前 10 个主成分)c-index 为 0.603,加入 PRS 后升至 0.670(似然比检验 P = 1.68 × 10-21)。
  • MP16 模型 c-index 为 0.713,MP16 + PRS 为 0.729(中位似然比检验 P = 5.56 × 10-11)。
  • 最高十分位中 MP16 + PRS 预测真病例 111 例、MP16 为 104 例;第二十分位分别为 72 例与 63 例。
  • 在 10–50% 各筛查阈值下,MP16 + PRS 较 MP16 的敏感性和/或特异性更高,净重分类改善范围为 0.01–0.05。

关键数值与推荐

  • PRS 优于任何单一临床危险因素:c-index 0.643。
  • 基线模型 c-index 0.603,加 PRS 后 0.670(LRT P = 1.68 × 10-21)。
  • MP16 c-index 0.713,MP16 + PRS 0.729(中位 LRT P = 5.56 × 10-11)。
  • 净重分类改善范围 0.01–0.05,筛查阈值 10–50%。

临床怎么用

  • 在黑色素瘤风险评估与筛查策略中,可考虑将 PRS 与 MP16 等临床风险模型联合使用以提升判别能力。
  • 光化性角化病治疗史与既往皮肤癌手术切除史是仅次于 PRS 的重要临床风险预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cutaneous melanoma is a common cancer, for which risk stratification has been proposed to aid early detection. OBJECTIVES: To assess the performance of a polygenic risk score (PRS) in predicting the risk of invasive cutaneous melanoma, alone and combined with clinical risk factors. METHODS: The PRS was derived from the most recent genome-wide association study meta-analysis of cutaneous melanoma, which included 28 849 patients with melanoma and 78 922 control participants from 20 studies from the UK, the USA, Australia and Europe. Then, it was tuned in the Canadian Longitudinal Studying on Aging cohort, which included 528 patients with melanoma and 17 787 control participants. The PRS was then tested independently against 14 self-reported clinical factors and a clinical prediction model (the MP16 model) in the QSkin prospective cohort, which included 16 282 participants with genetic data aged 40-69 years at baseline, among whom 359 were identified with new invasive melanomas during 10 years of follow-up. RESULTS: The PRS outperformed any other single clinical risk factor in QSkin (c-index 0.643). The baseline risk model (age, sex, first 10 principal components) had a c-index of 0.603; adding PRS to the baseline model increased the c-index to 0.670 [likelihood ratio test (LRT) P = 1.68 × 10-21]. Adding PRS to the MP16 model significantly enhanced discrimination [MP16 c-index: 0.713; MP16 + PRS c-index: 0.729 (median LRT P = 5.56 × 10-11)] and predicted more true cases in the first and second top deciles (111 for MP16 + PRS vs. 104 for MP16 in the first decile, and 72 for MP16 + PRS vs. 63 for MP16 in the second decile). Across various screening thresholds (10-50%), the sensitivity and/or specificity is higher and the net reclassification improvements were in the range of 0.01-0.05, comparing the MP16 + PRS model with the MP16 model. CONCLUSIONS: Incorporating genetic risk information into existing clinical risk tools significantly improves prediction performance for melanoma. Melanoma is a common and serious form of skin cancer. Most of the variation in who will and will not develop this type of cancer can be linked to the genes a person is born with. Scientists have developed a tool called a polygenic risk score (PRS) to estimate how much genetic risk a person has for developing melanoma. In this study, we created a more powerful PRS using advanced statistical methods. When we tested it, we found that it was the strongest predictor of melanoma risk. The second strongest predictor of melanoma risk was if the person had been treated for actinic keratosis. Actinic keratosis is a pre-cancerous skin condition. The third strongest predictor of melanoma risk was previous surgical removal of skin cancer. Adding the PRS to other known risk factors led to improvements in how well we could predict a person’s risk of melanoma. Our study comprehensively compares risk factors for melanoma. We also highlight the potential of PRS to be included in future melanoma risk prediction and screening strategies.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wang H, Ghajari H, Jayasinghe GJMSR, et al. Genetics versus clinical risk scores for melanoma prediction. Br J Dermatol. 2026. PMID: 41968088. doi:10.1093/bjd/ljag126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。